EDIT - Editas Medicine, Inc.

NasdaqGS - NasdaqGS Delayed price. Currency in USD
25.95
+0.49 (+1.92%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close25.46
Open25.63
Bid25.36 x 200
Ask25.95 x 200
Day's range25.60 - 26.58
52-week range13.12 - 29.20
Volume787,827
Avg. volume1,089,616
Market cap1.086B
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)-3.17
Earnings date6 Nov 2017 - 10 Nov 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est33.21
Trade prices are not sourced from all markets
  • Disruptor Alert: These 5 Companies Are Changing Healthcare
    Motley Fool8 days ago

    Disruptor Alert: These 5 Companies Are Changing Healthcare

    Healthcare won't be the same in the future because of these pioneers in gene editing, gene sequencing, and artificial intelligence.

  • Editas Medicine Keeps Moving Forward
    Motley Fool13 days ago

    Editas Medicine Keeps Moving Forward

    The biotech offered steady progress and no big surprises in its latest quarter -- and that's a good thing.

  • Here's Why Editas Medicine Collapsed at Market Open Today
    Motley Fool14 days ago

    Here's Why Editas Medicine Collapsed at Market Open Today

    The innovative biopharma announced third-quarter 2017 results Tuesday, but there weren't any surprises.

  • Associated Press15 days ago

    Editas reports 3Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 64 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing
    Investor's Business Daily2 months ago

    Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing

    Bluebird toppled to a four-week low Monday as an analyst downgraded the stock on doubts regarding its sickle cell disease drug.

  • Reuters - UK Focus7 months ago

    University of California files appeal over CRISPR patents

    The University of California is appealing a U.S. patent ruling over the game-changing gene editing technology known as CRISPR that favored the Broad Institute, a research affiliate of Harvard University and the Massachusetts Institute of Technology. The appeal filed in the U.S. Court of Appeals for the Federal Circuit was announced Thursday by the UC, the University of Vienna and handful of startup companies that have licensed its patents. Microbiologists Jennifer Doudna of the University of California, Berkeley, and Emmanuelle Charpentier of the University of Vienna were first to apply for patent in 2012 after discovering how the primitive bacterial system called CRISPR-Cas9 could be used to edit genomes in simple pieces of DNA (Frankfurt: 24D.F - news) called plasmids.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes